Allergan scratches expansion itch with $350 million SkinMedica offer

The end of the year M&A action seems to be on. Botox maker Allergan ($AGN) has agreed to pay $350 million to pick up skin products company, SkinMedica, Bloomberg reports. The announcement came the same day that U.K. consumer goods company Reckitt Benckiser Group said it would be willing to pay $1.4 billion to buy vitamin maker Schiff Nutrition International. That offer was an overbid of the $1.2 billion that drugmaker Bayer already extended for Schiff. The Allergan deal comes as the company is looking at getting out of the Lap-Band weight loss device market, a product that has been controversial and is seeing falling sales. Dermatology drugs and products are a popular area right now. In September, Valeant Pharmaceuticals ($VRX) said it would pay $2.6 billion to buy dermatology specialist Medicis Pharmaceutical. Story | More


Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.